Key result
In a preliminary cohort of 622 Chinese patients with arrhythmogenic cardiomyopathy and their relatives, 40.1% experienced malignant ventricular arrhythmias and 21.9% developed end-stage heart failure.
Why the study?
Arrhythmogenic cardiomyopathy patients in China have unique genetic and clinical features, but prognostic models specific to Chinese patients are lacking.
Cohort (n=622)
Yes
Answers are grounded in this paper and cite their sources.
The ChinaCORE ACM registry establishes a large, national cohort of Chinese patients with arrhythmogenic cardiomyopathy, revealing a high burden of malignant ventricular arrhythmias and end-stage heart failure.
BACKGROUND: Arrhythmogenic cardiomyopathy (ACM) patients in China exhibit unique genetic and clinical characteristics. There is a lack of prognostic models specific to Chinese ACM patients. OBJECTIVES: This study aims to establish a large, national ACM patient cohort with uniformly collected, high-quality data for future risk prediction. METHODS: This study includes patients with definite or borderline ACM diagnoses, along with their genotype-positive relatives. At baseline, comprehensive data collection includes medical history, electrocardiograms, imaging data, genetic testing, and laboratory evaluations. Outcome data include heart failure events and malignant ventricular arrhythmias. Imaging evaluation revealed RV dilatation in 44.6% and left ventricular dilatation in 29.8%, with a mean left ventricular ejection fraction of 53.0% ± 14.5%. Regarding outcomes, malignant ventricular arrhythmias occurred in 255 (40.1%) individuals, while 21.9% developed end-stage heart failure, including 35 individuals who died of heart failure and 101 patients who underwent heart transplantation. CONCLUSIONS: The ChinaCORE ACM (China Multi-Center Cohort Study on Risk Evaluation of Arrhythmogenic Cardiomyopathy) registry is a national, longitudinal, observational cohort study. This study contributes to expanding the understanding of the disease spectrum of Chinese ACM patients and improving prognostic predictions.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) conducted a cohort in Arrhythmogenic Cardiomyopathy (n=622). Arrhythmogenic Cardiomyopathy was evaluated on Malignant ventricular arrhythmias and end-stage heart failure. In a preliminary cohort of 622 Chinese patients with arrhythmogenic cardiomyopathy and their relatives, 40.1% experienced malignant ventricular arrhythmias and 21.9% developed end-stage heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: